TFC — Truist Financial Corporation

Constructive but unconvinced. The Q3 2026 print (filed 2026-10-16) was marginally soft — adjusted EPS $1.16 vs. $1.17 consensus, revenue +1.2% YoY to $5.3B, NIM (TE) 3.0% — yet the stock rose 1.07% to $47.07 on 2026-10-17 and +2.08% on the week, because investors keyed on the $1.0B of CET1 released by the RAC sale and the AFS swap from 2.67% to ~5.6% yields. That optimism is recent: TFC is still down 10.34% over three months, the rating breakdown is 27 buy / 24 hold / 3 sell, and consensus targets of ~$53-54 sit only ~14% above the 2026-10-17 price. The market credits the strategy but is not paying up for it.

Read earnings, not the reported revenue line, which is badly distorted by portfolio exits. Diluted EPS ground upward from $0.81 in Q1 2024 to $1.23 in Q2 2026, then dropped to $0.56 in Q3 2026 — a gap almost entirely explained by securities-repositioning and portfolio-sale charges, since adjusted EPS that quarter was $1.16 versus $0.90 a year earlier. Operating income tracks the same path: $1.365B (Q1 2024) to $1.815B (Q2 2026, the best quarter in the window), then $895M in Q3 2026. Total revenue fell from $7.844B in Q3 2025 to $6.114B in Q3 2026 on the FMP basis, but that is a deliberately shrinking balance sheet, not demand destruction. The $1.139B revenue / -$5.23B operating income in Q2 2024 and the -$5.09B net loss in Q4 2023 are one-offs (insurance-unit sale and goodwill impairment) and should be stripped out of any trend. Verdict: genuinely improving underlying momentum through mid-2026, with Q3 2026 a charge-driven blip that will suppress reported growth for another two to four quarters while sold portfolios roll off.

Cheap in absolute terms, only fair versus its own history. At the 2026-10-17 price of $47.07, TFC trades at 11.98x trailing EPS of $4.286 — essentially identical to its 4-year average of 12.07x — and 10.0x FY2027 consensus EPS of $4.698. Price/book is 0.927x against roughly $50.32 of book value per share, price/sales of 2.0x sits below the 5-year average of 2.41x, and the dividend yields 3.92%. The PEG of 2.65 is noise: trailing growth is negative and divestiture-distorted, so it says nothing about expensiveness. The honest framing is that 0.93x book on an 8.1% ROE is roughly where a bank earning at — not above — its cost of equity should trade. There is no multiple-based cushion; the entire case has to be an earnings/ROE recovery case.

At $47.07 on 2026-10-17 the stock is capitalizing $4.698 of FY2027 EPS at 10.0x, well below the ~12x at which the market has historically valued TFC's earnings. That means the ROTCE-to-15%-by-2027 plan is being discounted heavily — if Truist actually delivers $5.50-6.00 of 2028 EPS and earns a 12x multiple, the stock is a $66-72 story, so the current price embeds real skepticism. The flip side is that 10x forward leaves almost no cushion: a credit surprise or a failed margin inflection re-rates it toward 8-9x quickly. Also expect noisy headlines — Q3 2026 GAAP EPS of $0.56 versus $1.16 adjusted shows restructuring charges will make the reported number look ~50% worse than true earnings power for several quarters, and screeners will keep flagging 'EPS misses' that aren't operational misses.

As of 2026-10-17, TFC closed at $47.07 (+1.07% on the day, +2.08% on the week) with RSI(14) at 47.5 — dead neutral, neither oversold nor overbought. It sits 0.83% above its 20-day SMA but 4.27% below its 50-day (~$49.2) and 5.10% below its 200-day (~$49.6): a medium-term downtrend with a short-term bounce, in the lower third of the $42.70-$56.20 52-week range. The -10.34% three-month and -6.92% six-month returns confirm the drift. Timing implication: no urgency and no oversold snapback setup — a patient buyer can wait for a reclaim of the 50-day near $49 as confirmation, or for a retest of the low-$40s where the yield and book-value support get materially more attractive.

• Net interest margin and the rate path: NIM (TE) was 3.0% in Q3 2026; the $8.6B AFS swap from 2.67% to ~5.6% yields is a mechanical NII tailwind over coming quarters, but Fed cuts would compress deposit spreads and partially offset it.
• Credit quality and consumer health: non-performing loans fell sharply after the RAC auto sale and the pending LightStream exit removes $7.7B of unsecured consumer risk, but commercial real estate — office especially — remains the sector's central unknown.
• Capital and regulation: CET1 finished Q3 2026 at 10.7%; buyback capacity ($1.2B repurchased in the quarter alone) depends on the stress capital buffer outcome and any Basel III endgame recalibration.
• Regional-bank sector rotation and consolidation: deposit competition, relative funding costs and M&A speculation drive group-wide multiple moves; Truist's Southeastern/Mid-Atlantic footprint is a structural positive in a slower-growth national economy.
• Revenue mix shift: post-divestitures, fee income from wealth, trust and insurance is a smaller share of the total, leaving the earnings base more rate-sensitive than it was three years ago.

• Closing and financial settlement of the $7.7B LightStream unsecured personal loan sale — releases capital and removes an earnings-volatility source.
• Net interest income progression over the next two to three quarters as the repositioned $8.6B securities portfolio seasons at ~5.6% yields.
• Q4 2026 results on 2027-01-20 (estimated) — the first clean, post-charge read and the key checkpoint on the 15% ROTCE-by-2027 roadmap.
• Continued share repurchases ($1.2B in Q3 2026) compounding EPS and book value per share at a sub-book price.
• Further efficiency actions or additional portfolio exits that shorten the path to a double-digit ROTCE.

• Credit deterioration — office CRE, residual consumer exposure, or a recession driving provision expense well above current levels.
• Execution risk on the restructuring: if the divested portfolios remove more earnings than the reinvestment adds back, ROTCE stalls below 10% and the discount to book never closes.
• A rate-cutting cycle compressing NIM faster than the securities repositioning helps, undercutting the core earnings-growth thesis.
• Value-trap risk: Truist has a multi-year record of earning roughly at or below its cost of equity; 0.93x book can stay 0.93x book for years absent a real ROE inflection.
• Regulatory capital changes (stress capital buffer, Basel III endgame) that restrict buybacks or force capital retention.

Not a table-pounding buy, but a defensible risk/reward for a patient income investor. You are paying ~10x forward EPS and 0.93x book for a bank whose 8.1% ROE is only now being deliberately rebuilt — the RAC exit, the LightStream sale and the 2.67%→5.6% securities swap are quantified actions rather than slideware, and $1.2B of quarterly buybacks at sub-book prices compound them. The catch is that my fair value near $52 implies only ~10% upside plus the 3.9% yield, and the January 2027 print is the first real proof point. Own it for yield and ROE-recovery optionality, not for near-term price momentum.

Applied an 11.0x forward P/E — a modest discount to the stock's own 4-year average of 12.07x, warranted by an 8.1% ROE that sits at or just below cost of equity — to the FY2027 consensus EPS of $4.698, producing $51.68. Two cross-checks: that figure equals ~1.03x the $50.32 per-share book value, consistent with a justified P/B for a bank earning toward a high-single/low-double-digit ROE, and it sits just below the $53-54 analyst consensus target, implying roughly 10% upside plus the 3.92% dividend.